FAST NEWS: Everest Medicines gets new drug license from Kezar Life
The latest: Everest Medicines Ltd. (1952.HK) announced Thursday that it has received an exclusive license from Kezar Life Sciences (KZR.US) to develop, manufacture and commercialize Zetomipzomib, a treatment for autoimmune diseases,…
FAST NEWS: Everest Medicines Hits New Low after New CEO Announcement
The latest: Innovative drug maker Everest Medicines Ltd. (1952.HK) on Monday announced the appointment of Luo Yongqing, formerly president and general manager of Greater China for Brii Biosciences Ltd. (2137.HK),…
Everest Medicines Descends to New Depths on String of Bad News
The drug maker’s shares hit all-time lows after it announced the loss of a key product, poor financial results and the resignation of its CEO Key Takeaways: The CEO of…
FAST NEWS: Everest Medicines Plunges After Terminating Breast Cancer Drug Deal
The latest: Everest Medicines Ltd. (1952.HK) announced Tuesday that it is terminating its agreement to develop Gilead Science’s (GILD.US) Sacituzumab Govitecan breast cancer drug for the China market. Looking up:…
Recent Articles
RELATED ARTICLES
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK -
Everest reaches new heights on growing drug sales
1952.HK
-
FAST NEWS: Everest Medicines loss widens on drug commercialization
1952.HK
- Health Guard plans dual listing to fund HPV vaccine fight
-
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
HBM gets health boost from drug licensing deals
2142.HK
